Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects
Top Cited Papers
- 15 June 2011
- journal article
- research article
- Published by Springer Nature in Psychopharmacology
- Vol. 218 (4) , 649-665
- https://doi.org/10.1007/s00213-011-2358-5
Abstract
Rationale This dose-effect study extends previous observations showing that psilocybin can occasion mystical-type experiences having persisting positive effects on attitudes, mood, and behavior. Objectives This double-blind study evaluated psilocybin (0, 5, 10, 20, 30 mg/70 kg, p.o.) administered under supportive conditions. Methods Participants were 18 adults (17 hallucinogen-naïve). Five 8-h sessions were conducted individually for each participant at 1-month intervals. Participants were randomized to receive the four active doses in either ascending or descending order (nine participants each). Placebo was scheduled quasi-randomly. During sessions, volunteers used eyeshades and were instructed to direct their attention inward. Volunteers completed questionnaires assessing effects immediately after and 1 month after each session, and at 14 months follow-up. Results Psilocybin produced acute perceptual and subjective effects including, at 20 and/or 30 mg/70 kg, extreme anxiety/fear (39% of volunteers) and/or mystical-type experience (72% of volunteers). One month after sessions at the two highest doses, volunteers rated the psilocybin experience as having substantial personal and spiritual significance, and attributed to the experience sustained positive changes in attitudes, mood, and behavior, with the ascending dose sequence showing greater positive effects. At 14 months, ratings were undiminished and were consistent with changes rated by community observers. Both the acute and persisting effects of psilocybin were generally a monotonically increasing function of dose, with the lowest dose showing significant effects. Conclusions Under supportive conditions, 20 and 30 mg/70 kg psilocybin occasioned mystical-type experiences having persisting positive effects on attitudes, mood, and behavior. Implications for therapeutic trials are discussed.Keywords
This publication has 31 references indexed in Scilit:
- Hallucinogens as MedicineScientific American, 2010
- Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months laterJournal of Psychopharmacology, 2008
- Human hallucinogen research: guidelines for safetyJournal of Psychopharmacology, 2008
- Dimensions of the Mysticism Scale: Confirming the Three‐Factor Structure in the United States and IranJournal for the Scientific Study of Religion, 2001
- Do hallucinogens cause residual neuropsychological toxicity?Drug and Alcohol Dependence, 1999
- The Standardized Psychometric Assessment of Altered States of Consciousness (ASCs) in HumansPharmacopsychiatry, 1998
- The Psychopharmacology of HallucinogensNeuropsychopharmacology, 1996
- Evidence for 5-HT2 involvement in the mechanism of action of hallucinogenic agentsLife Sciences, 1984
- Toward a Theory of Death TranscendenceJournal for the Scientific Study of Religion, 1983
- The Wondrous Mushroom. Mycolatry in MesoamericaMycologia, 1981